SRSF2 and acute myeloid leukemia: SRSF2 is mutated in 50% of patients with CMML, 10–14% of patients with AML, and 20–30% of patients with MDS (Yoshida et al., 2011), where these mutations confer an increased risk of transformation from MDS to AML (Papaemmanuil et al., 2013).